Bcl-xL is associated with the anti-apoptotic effect of IL-15 on the survival of CD56dim natural killer cells

Molecular Immunology

Volumn 45, Issue 9, 2008, Pages 2559-2569

  Zheng, Xiaodong ^a   Wang, Yanyan ^a   Wei, Haiming ^a   Ling, Bin ^b   Sun, Rui ^a   Tian, Zhigang ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Apoptosis; Bcl xL; CD56dim NK; IL 15; IL 2

Indexed keywords

CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOCORTIN 5; PROTEIN BCL XL;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL CORD BLOOD; UPREGULATION;

ANTIGENS, CD56; APOPTOSIS; BCL-X PROTEIN; CELL SURVIVAL; CELLS, CULTURED; FETAL BLOOD; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS;

EID: 40849151855     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.01.001     Document Type: Article

References (53)

1. Akashi K., Kondo M., Freeden-Jeffry U., Murray R., and Weissman I.L. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89 (1997) 1033-1041
2. Assarsson E., Kambayashi T., Schatzle J.D., Cramer S.O., von B.A., Jensen P.E., Ljunggren H.G., and Chambers B.J. NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J. Immunol. 173 (2004) 174-180
3. Berard M., Brandt K., Bulfone-Paus S., and Tough D.F. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J. Immunol. 170 (2003) 5018-5026
4. Bulfone-Paus S., Ungureanu D., Pohl T., Lindner G., Paus R., Ruckert R., Krause H., and Kunzendorf U. Interleukin-15 protects from lethal apoptosis in vivo. Nat. Med. 3 (1997) 1124-1128
5. Burkett P.R., Koka R., Chien M., Chai S., Boone D.L., and Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med. 200 (2004) 825-834
6. Cantrell D.A., and Smith K.A. The interleukin-2 T-cell system: a new cell growth model. Science 224 (1984) 1312-1316
7. Carson W.E., Fehniger T.A., Haldar S., Eckhert K., Lindemann M.J., Lai C.F., Croce C.M., Baumann H., and Caligiuri M.A. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99 (1997) 937-943
8. Chan A., Hong D.L., Atzberger A., Kollnberger S., Filer A.D., Buckley C.D., McMichael A., Enver T., and Bowness P. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J. Immunol. 179 (2007) 89-94
9. Chao D.T., and Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16 (1998) 395-419
10. Chiossone L., Vitale C., Cottalasso F., Moretti S., Azzarone B., Moretta L., and Mingari M.C. Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood 109 (2007) 3767-3775
11. Cooper M.A., Fehniger T.A., and Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 22 (2001) 633-640
12. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., and Caligiuri M.A. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 (2001) 3146-3151
13. Cooper M.A., Bush J.E., Fehniger T.A., VanDeusen J.B., Waite R.E., Liu Y., Aguila H.L., and Caligiuri M.A. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100 (2002) 3633-3638
14. Cooper M.A., Fehniger T.A., Fuchs A., Colonna M., and Caligiuri M.A. NK cell and DC interactions. Trends Immunol. 25 (2004) 47-52
15. Cornish G.H., Sinclair L.V., and Cantrell D.A. Differential regulation of T-cell growth by IL-2 and IL-15. Blood 108 (2006) 600-608
16. Davey G.M., Kurts C., Miller J.F., Bouillet P., Strasser A., Brooks A.G., Carbone F.R., and Heath W.R. Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J. Exp. Med. 196 (2002) 947-955
17. D'Cruz L.M., and Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6 (2005) 1152-1159
18. Demirci G., and Li X.C. IL-2 and IL-15 exhibit opposing effects on Fas mediated apoptosis. Cell Mol. Immunol. 1 (2004) 123-128
19. d'Ettorre G., Forcina G., Lichtner M., Mengoni F., D'Agostino C., Massetti A.P., Mastroianni C.M., and Vullo V. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. AIDS 16 (2002) 181-188
20. Dubois S., Mariner J., Waldmann T.A., and Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17 (2002) 537-547
21. Fehniger T.A., and Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood 97 (2001) 14-32
22. Fehniger T.A., Cooper M.A., Nuovo G.J., Cella M., Facchetti F., Colonna M., and Caligiuri M.A. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101 (2003) 3052-3057
23. Fontenot J.D., Rasmussen J.P., Gavin M.A., and Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6 (2005) 1142-1151
24. Freud A.G., Becknell B., Roychowdhury S., Mao H.C., Ferketich A.K., Nuovo G.J., Hughes T.L., Marburger T.B., Sung J., Baiocchi R.A., Guimond M., and Caligiuri M.A. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22 (2005) 295-304
25. Friberg D.D., Bryant J.L., and Whiteside T.L. Measurements of natural killer (NK) activity and NK-cell quantification. Methods 9 (1996) 316-326
26. Giri J.G., Ahdieh M., Eisenman J., Shanebeck K., Grabstein K., Kumaki S., Namen A., Park L.S., Cosman D., and Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13 (1994) 2822-2830
27. Giri J.G., Kumaki S., Ahdieh M., Friend D.J., Loomis A., Shanebeck K., DuBose R., Cosman D., Park L.S., and Anderson D.M. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14 (1995) 3654-3663
28. Goodier M.R., Imami N., Moyle G., Gazzard B., and Gotch F. Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone. Clin. Exp. Immunol. 134 (2003) 470-476
29. Grayson J.M., Zajac A.J., Altman J.D., and Ahmed R. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells. J. Immunol. 164 (2000) 3950-3954
30. Hildeman D.A., Zhu Y., Mitchell T.C., Kappler J., and Marrack P. Molecular mechanisms of activated T cell death in vivo. Curr. Opin. Immunol. 14 (2002) 354-359
31. Jacobs R., Hintzen G., Kemper A., Beul K., Kempf S., Behrens G., Sykora K.W., and Schmidt R.E. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur. J. Immunol. 31 (2001) 3121-3127
32. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., Matsuki N., Charrier K., Sedger L., Willis C.R., Brasel K., Morrissey P.J., Stocking K., Schuh J.C., Joyce S., and Peschon J.J. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191 (2000) 771-780
33. Koopman L.A., Kopcow H.D., Rybalov B., Boyson J.E., Orange J.S., Schatz F., Masch R., Lockwood C.J., Schachter A.D., Park P.J., and Strominger J.L. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J. Exp. Med. 198 (2003) 1201-1212
34. Kundig T.M., Schorle H., Bachmann M.F., Hengartner H., Zinkernagel R.M., and Horak I. Immune responses in interleukin-2-deficient mice. Science 262 (1993) 1059-1061
35. Lanier L.L., Le A.M., Civin C.I., Loken M.R., and Phillips J.H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136 (1986) 4480-4486
36. Lenardo M.J. Fas and the art of lymphocyte maintenance. J. Exp. Med. 183 (1996) 721-724
37. Li X.C., Demirci G., Ferrari-Lacraz S., Groves C., Coyle A., Malek T.R., and Strom T.B. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7 (2001) 114-118
38. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243 (2000) 147-154
39. Ma A., Boone D.L., and Lodolce J.P. The pleiotropic functions of interleukin 15: not so interleukin 2-like after all. J. Exp. Med. 191 (2000) 753-756
40. Marks-Konczalik J., Dubois S., Losi J.M., Sabzevari H., Yamada N., Feigenbaum L., Waldmann T.A., and Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 11445-11450
41. Marrack P., and Kappler J. Control of T cell viability. Annu. Rev. Immunol. 22 (2004) 765-787
42. Masuda A., Matsuguchi T., Yamaki K., Hayakawa T., and Yoshikai Y. Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression. J. Biol. Chem. 276 (2001) 26107-26113
43. Ogata Y., Kukita A., Kukita T., Komine M., Miyahara A., Miyazaki S., and Kohashi O. A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J. Immunol. 162 (1999) 2754-2760
44. Pala P., Hussell T., and Openshaw P.J. Flow cytometric measurement of intracellular cytokines. J. Immunol. Methods 243 (2000) 107-124
45. Romagnani C., Juelke K., Falco M., Morandi B., D'Agostino A., Costa R., Ratto G., Forte G., Carrega P., Lui G., Conte R., Strowig T., Moretta A., Munz C., Thiel A., Moretta L., and Ferlazzo G. CD56brightCD16- killer Ig-like receptor NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J. Immunol. 178 (2007) 4947-4955
46. Schimpl A., Berberich I., Kneitz B., Kramer S., Santner-Nanan B., Wagner S., Wolf M., and Hunig T. IL-2 and autoimmune disease. Cytokine Growth Factor Rev. 13 (2002) 369-378
47. Tarazona R., Casado J.G., Delarosa O., Torre-Cisneros J., Villanueva J.L., Sanchez B., Galiani M.D., Gonzalez R., Solana R., and Pena J. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J. Clin. Immunol. 22 (2002) 176-183
48. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47 (1989) 187-376
49. Umemura M., Nishimura H., Yajima T., Wajjwalk W., Matsuguchi T., Takahashi M., Nishiyama Y., Makino M., Nagai Y., and Yoshikai Y. Overexpression of interleukin-15 prevents the development of murine retrovirus-induced acquired immunodeficiency syndrome. FASEB J. 16 (2002) 1755-1763
50. Vankayalapati R., Klucar P., Wizel B., Weis S.E., Samten B., Safi H., Shams H., and Barnes P.F. NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J. Immunol. 172 (2004) 130-137
51. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6 (2006) 595-601
52. Weber K., Meyer D., Grosse V., Stoll M., Schmidt R.E., and Heiken H. Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology 202 (2000) 172-178
53. Yu H., Fehniger T.A., Fuchshuber P., Thiel K.S., Vivier E., Carson W.E., and Caligiuri M.A. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 92 (1998) 3647-3657